Misplaced Pages

Melevodopa

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Melevodopa
Clinical data
Trade namesLevomet
Other namesLevodopa methyl ester; L-DOPA methyl ester; LDME; CHF-1301
ATC code
Identifiers
IUPAC name
  • methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO4
Molar mass211.217 g·mol
3D model (JSmol)
SMILES
  • O=C(OC)(N)Cc1cc(O)c(O)cc1
InChI
  • InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1
  • Key:XBBDACCLCFWBSI-ZETCQYMHSA-N
  (verify)

Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa. It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa. In combination with carbidopa, as melevodopa/carbidopa (brand name Sirio), it is approved for use in the treatment of Parkinson's disease.

See also

References

  1. Buckingham J, Baggaley K, Roberts A, Szabo L (2010). Dictionary of Alkaloids with CD-ROM. CRC Press. p. 103. ISBN 978-1-4200-7770-4. Retrieved 28 September 2024.
  2. Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
  3. Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clin Neuropharmacol. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
  4. "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
  5. "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.


Antiparkinson agents (N04)
Dopaminergics
DA precursors
DA receptor agonists
MAO-B inhibitors
COMT inhibitors
AAAD inhibitors
Anticholinergics
Others
Dopamine receptor modulators
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Phenethylamines
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
Phenylalkylpyrrolidines
Catecholamines
(and close relatives)
Miscellaneous


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: